Physicochemical Properties
| Molecular Formula | C28H28FN7 |
| Molecular Weight | 481.57 |
| Appearance | Typically exists as solid at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Menin-MLL inhibitor-25 (compound A6) (0-10 µM) exhibits antiproliferative activity with IC50 values of 1.07, >10, and 6.7 µM< sup> for MV4-11, HL-60, and SU-DHL-6 cells, respectively [1]. Menin-MLL inhibitor-25 (0.1, 1, 10 µM; 24 h) induces apoptosis and cell cycle arrest at the G0/G1 phase of MV4-11 cells [1]. Menin-MLL inhibitor-25 (0.1, 0.5 µM; 24, 48 h) reduces HOXA9 and MEIS1 gene expressions in a time- and dose-dependent manner [1]. |
| Cell Assay |
Cell Viability Assay[1] Cell Types: MV4-11, HL-60, SU-DHL-6 cells Tested Concentrations: 0-10 µM Incubation Duration: Experimental Results: Showed anti-proliferation activity with IC50s of 1.07, >10, 6.7 µM for MV4-11, HL-60, SU-DHL-6 cells, respectively. Apoptosis Analysis[1] Cell Types: MV4-11 cells Tested Concentrations: 0.1, 1, 10 µM Incubation Duration: 24 h Experimental Results: Induced apoptosis with the apoptosis rates of 6.09 %, 8.86 % and 43.08 % at 0.1, 1 and 10 μM. Cell Cycle Analysis[1] Cell Types: MV4-11 cells Tested Concentrations: 0.01, 0.1, 1 µM Incubation Duration: 24 h Experimental Results: Induced cell cycle arrest at G0/G1 phase in a dose-dependent manner. RT-PCR[1] Cell Types: MV4-11 cells Tested Concentrations: 0.1, 0.5 µM Incubation Duration: 24, 48 h Experimental Results: Decreasesd the gene expression of HOXA9 and MEIS1 in a time and dose dependent manner. |
| References |
[1].Discovery of novel pyrrolo[2,3-d]pyrimidines as potent menin-mixed lineage leukemia interaction inhibitors. Eur J Med Chem. 2024 Feb 8;268:116226. |
Solubility Data
| Solubility (In Vitro) | Typically soluble in DMSO (e.g. 10 mM) |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0765 mL | 10.3827 mL | 20.7654 mL | |
| 5 mM | 0.4153 mL | 2.0765 mL | 4.1531 mL | |
| 10 mM | 0.2077 mL | 1.0383 mL | 2.0765 mL |